Commissioner for Patents, Box PCT United States Patent and Trademark Office Washington, D.C. 20231

TOTAL STATE OF THE PARTY OF THE	FIRST NAMED APPLICANT	ATTY, DOCKET NO.		
U.S. APPLICATION NO.	FIRST NAMED AFFICANT			
09/806368	KATSUURA	M · 447.001		
		INTERNATIONAL APPLICATION NO.		
BIERMAN MUSERLIAN AND L	UCAS ~ FROM WITH	PCT/IB99/01621		
600 THIRD AVENUE	0)19050000			
NEW YORK, NY 10016		I.A. FILING DATE PRIORITY DATE		
	Charles Live	04 OCT 99 09 OCT 98		
1	BIERMAN, MUSERLIAN AND LUCA	S DATE MAILED: 13 SEP 2001		
		R 35 U.S.C. 371 IN THE UNITED		
	DESIGNATED/ELECTED OFF	· · · · · · · · · · · · · · · · · · ·		
Office as a Designated C	submitted by the applicant or the IB to the UDffice (37 CFR 1.494) R an Elected Offi	onited States Patent and Trademark		
** 0 D - N - 1 D				
Commendation		ernational application into English.		
Oath or Declaration of	_	e 19 amendments into English.		
Copy of Article 19 ame		•		
Priority Document.	0			
	ninary Examination Report in English and i	its Annexes, if any.		
Translation of Annexes	to the International Preliminary Examination	on Report into English.		
		Challes Calleria in the disease of the control of t		
		not filed the following indicated items and/or		
prior to 20 or 30 months from the p		of the international application must be filed		
U.S. Basic National Fe		onal application.		
	· ·			
	urnished within the period set forth below it	n order to complete the requirements for		
acceptance under 35 U.S.C. 371:	plication into English. A processing fee wi	ill be required if submitted		
	ropriate 20 or 30 months from the priority of			
The current transl	ation is defective for the reasons indicated of	on the attached Notice of Defective		
Translation.		die de Access lessados de		
	roviding the translation of the application ar			
appropriate 20 or	30 months from the priority date (37 CFR of the inventors, in compliance with 37 CFR	1.492(I)). R 1.497(a) and (b) properly identifying		
the application (p	referably by the International application nu	imber and international filing date). A		
surcharge will be	required if submitted later than the appropr	riate 20 or 30 months from the priority		
date.		•		
	or declaration does not comply with 37 CFI ttached PCT/DO/EO/917.	R 1.49/(a) and (b) for the reasons		
		poropriate 20 or 30 months from the		
 d. Surcharge for providing the oath or declaration later than the appropriate 20 or 30 months from the priority date (37 CFR 1.492(e)). 				
4. Additional claim fees of \$ as a large entity small entity, including any required multiple dependent				
claim fee, are required. Applicant must submit the additional claim fees or cancel the additional claims for which fees are				
due (37 CFR 1.492(g)). See attache	ed PIO-875.			
5. 🛪 Applicant has not submitted t	the required sequence listing pursuant to 37	CFR 1.821-1.825. See attached		
PCT/DO/EO/920.	. ,			
		DAY OF THE STATE O		
MONTHS FROM THE DATE OF	TH IN 3(a)-3(d), 4 AND 5 ABOVE MUST F THIS NOTICE OR BY 22 OR 32 MON	THS (where 37 CFR 1.495 applies) FROM		
	E APPLICATION, WHICHEVER IS LA			
RESPOND WILL RESULT IN A				
The time period set above may be e	extended by filing a petition and fee for exte	ension of time under the provisions of 37 CFR		
1.136(a).	Attended by firing a petition and fee for exte	install of time under the provisions of 57 Gra		
• •				
6. If box 3a or 3c is checked, a translation of the Annexes MUST be submitted no later than the time period set above or the Annexes will be cancelled. A processing fee will be required if submitted later than 20 or 30 months from the priority date.				
7. The Article 19 amendments are cancelled since a translation was not provided by the appropriate 20 (37 CFR 1.494(d))				
or 30 (37 CFR 1.495(d)) months from the priority date.				
Applicant is reminded that any communication to the United States Patent and Trademark Office must be mailed to the Nov 13 of				
addieso Biron in the nearing and metade are dies approximent in the sile of th				
A copy of	this notice MUST be returned	with this response. (+1) Dec 13 The shelby J. Vigil (+3) FeB 13		
Enclosed: PCT/DO/EO/917	Notice of Defective Translatio	n (\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \		
☐ PTO-875	PCT/DO/EO/920	Shallow I Visit C \\ \\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\		
	_	Shelby J. Vigil () (+3) FeB 13		
FORM PCT/DO/EO/905 (March 2	UU1) Telephor	ne: 703-305-3653 (+4) Man 15 pt		
*	•	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\		

Commissioner for Patents, Box United States Patent and Trademark C Washington, D.C. 2

U.S. APPLICATION NO.	FIRST NAMED APPLICANT		ATTY, DOCKET NO.
09/806368	KATSUURA	М	447.001
		INTERNATIONA	L APPLICATION NO.
BIERMAN MUSERLIAN AND LUCAS 600 THIRD AVENUE		PCT/IB99/01621	
NEW YORK, NY 10016	•	I.A. FILING DATE	PRIORITY DATE
		04 OCT 99	09 OCT 98
		DATE MAILED:	13 SEP 2001

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

M	The application fails to comply with the requirements of 37 CFR 1.821-1.825.
	This application does not contain, a "Sequence Listing" as a separate part of the
- -\	disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
	A copy of the "Sequence Listing" in computer readable format has not been submitted as
	required by 37 CFR 1.821(e).
	A copy of the "Sequence Listing" in computer readable form has been submitted. The
	content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
\Box	The computer readable form that has been filed with this application has been found to be
	damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
Ш	The paper copy or compact disc of the "Sequence Listing" is not the same as the
	computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
Ш	Other:
ICA	NT MUST PROVIDE:
X	An initial or substitute computer readable form (CRF) of the "Sequence Listing."

APPL

An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.

A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CALL:

(703) 308-4216, for Rules interpretation,

(703) 308-4212, for CRF submission help,

(703) 287-0200, for PatentIn software help.

Telephone: 703-305-3653